Positive (and negative) data a highlight of Subspecialty Day
Investigational trials target VEGF/angiopoietin2 inhibition
Povidone iodine reapplication: Protocol for preventing endophthalmitisTake-Home Message: A pearl for preventing endophthalmitis following intravitreal injections: avoid eyelid contact with the injection site after the last application of povidone iodine.
Hypersonic vitrector holds potential for multiple benefitsBausch + Lomb has introduced an ultrasonic-powered hypersonic vitrectomy system that is driven exclusively by the company’s Stellaris Elite Vision Enhancement System. It has a novel mechanism of action and is expected to offer advantages compared with guillotine vitrectors, according to the company.
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Novel DME treatment derives from multimodal activityALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Study finds YAG laser vitreolysis may be option for floatersTake-Home Message: YAG laser vitreolysis might be a treatment option for patients with complaints of floaters. Larger studies of longer duration are needed to corroborate these results.
Connect with ARVO colleagues during AAO
var script= ' ';